ADC ID	DRG0TKVCB
ADC Name	Loncastuximab tesirine
Brand Name	Zynlonta
Synonyms	loncastuximab tesirine; ADCT-402; RB4v1.2-SG-3249; Zynlonta; loncastuximab tesirine-lpyl; MT-2111; Lonca    Click to Show/Hide
Organization	ADC Therapeutics (Originator);Tanabe Pharma Corporation;Swedish Orphan Biovitrum;Spirogen (Top20 MNC);Overland Pharmaceuticals
Drug Status	Approved in 2021
Drug-to-Antibody Ratio	2.3
Structure
				2D MOL
Antibody Name	Loncastuximab					Antibody Info
Antigen Name	B-lymphocyte antigen CD19 (CD19)					Antigen Info
Payload Name	SG3199 (SC-DR002)					Payload Info
Therapeutic Target	Human deoxyribonucleic acid (hDNA)					Target Info
Linker Name	Mal-PEG8-Val-Ala-PABC					Linker Info
Conjugate Type	Random Cysteines
Combination Type	tesirine
Absorption	For loncastuximab tesirine, mean Cmax=2995 (ug/L) during cycle 1, mean Cmax=3155 (ug/L) during cycle 2; AUC=15,245-22,823 (day x ug/L).
Distribution	The monoclonal antibody portion of loncastuximab tesirine-lpyl is catabolized into small peptides. In vitro studies show that the small molecule cytotoxin portion, SG3199, is metabolized by CYP3A4/5. The half-life of loncastuximab tesirine-lpyl was 7.06-12.5 days at steady-state.
Metabolism	The monoclonal antibody portion of loncastuximab tesirine-lpyl is catabolized into small peptides. In vitro studies show that the small molecule cytotoxin portion, SG3199, is metabolized by CYP3A4/5. The half-life of loncastuximab tesirine-lpyl was 7.06-12.5 days at steady-state.
Toxicity	The main excretion pathways of SG3199 have not been formally studied in humans. SG3199 is thought to be minimally excreted by the kidneys. The mean clearance of loncastuximab tesirine-lpyl were 0.499 L/day (after a single dose) and 0.275 L/day (at steady-state).
Special Approval(s)	Priority review (FDA); Accelerated approval (FDA); Orphan drug (FDA); Orphan drug (EMA)

Dissocation Constant (Kd)	Binding Target	Description	Reference
Undisclosed	CD19	CD19-expressing Ramos cells exposed to ADCT-402 (1 hour at 4°C) showed prominent cell surface binding	[1]

Bystander Killing Effect	Description	Reference
yes	Ramos cells were treated with ADCT-402 for 1, 2, or 3 days, and the media was transferred onto CD192 Karpas-299 cells for 96 hours. The ADCT-402 conditioned medium induced a bystander effect after 1 day of pretreatment, as shown by a decrease in survival percentage in Karpas-299 cells compared to nonconditioned medium (100% to 86). This effect was stronger after 2 or 3 days of pretreatment, with a further decrease in survival percentage (80% and 65%, P =0.001). Conversely, conditioned medium from ADCT-402-treated CD192 NCI-N87 cells did not induce a bystander effect on Karpas-299 cells, regardless of preincubation time.    Click to Show/Hide	[1]

Standard Type	Value	Units	Description	Reference
Maximum Observed Concentration (Cmax)	1776	ng/mL	After loncastuximab tesirine treatment with the recommended dose regimen, the Cmax are 2911 ng/mL; the Cmax at steady state are 1776 ng/mL.	[1], [2]
Area Under the Concentration-Time Curve (AUC)	16882	ng*day/mL	After loncastuximab tesirine treatment with the recommended dose regimen, the AUC in cycle 2 are 21,665 ng·day/mL; the AUC at steady state are 16,882 ng·day/mL	[1], [2]
Maximum Observed Concentration (Cmax)	2841	ng/mL	150 Ug/kg Q3W,Dose-related exposure. Administered to patients with relapsed/refractory (R/R) B-cell malignancies. In Cycle 1,	[3]
Maximum Observed Concentration (Cmax)	3258	ng/mL	150 Ug/kg Q3W,Dose-related exposure. Administered to patients with relapsed/refractory (R/R) B-cell malignancies. In Cycle 2,	[3]
Area Under the Concentration-Time Curve (AUC)	10329	ng*day/mL	150 Ug/kg Q3W,Dose-related exposure. Administered to patients with relapsed/refractory (R/R) B-cell malignancies. In Cycle 1,	[3]
Area Under the Concentration-Time Curve (AUC)	16547	ng*day/mL	150 Ug/kg Q3W,Dose-related exposure. Administered to patients with relapsed/refractory (R/R) B-cell malignancies. In Cycle 2,	[3]
Maximum Observed Concentration (Cmax)	2430	ng/mL	150 Ug/kg Q3W for two cycles, 75 ug/kg Q3W for subsequent cycles,Administered to patients with R/R B-cell malignancies. Dose reduced from 150 ug/kg to 75 ug/kg in cycle 1.	[3]
Maximum Observed Concentration (Cmax)	2734	ng/mL	150 Ug/kg Q3W for two cycles, 75 ug/kg Q3W for subsequent cycles,Administered to patients with R/R B-cell malignancies. Dose reduced from 150 ug/kg to 75 ug/kg in cycle 2.	[3]
Maximum Observed Concentration (Cmax)	1694	ng/mL	150 Ug/kg Q3W for two cycles, 75 ug/kg Q3W for subsequent cycles,Administered to patients with R/R B-cell malignancies. Dose reduced from 150 ug/kg to 75 ug/kg in cycle 3.	[3]
Area Under the Concentration-Time Curve (AUC)	15850	ng*day/mL	150 Ug/kg Q3W for two cycles, 75 ug/kg Q3W for subsequent cycles,Administered to patients with R/R B-cell malignancies. Dose reduced from 150 ug/kg to 75 ug/kg in cycle 1.	[3]
Area Under the Concentration-Time Curve (AUC)	23913	ng*day/mL	150 Ug/kg Q3W for two cycles, 75 ug/kg Q3W for subsequent cycles,Administered to patients with R/R B-cell malignancies. Dose reduced from 150 ug/kg to 75 ug/kg in cycle 2.	[3]
Maximum Observed Concentration (Cmax)	659	ng/mL	Loncastuximab tesirine 60 ug/kg once Q3W and ibrutinib 560 mg/day, Administered to patients with R/R B-cell malignancies in cycle 1.	[3]
Maximum Observed Concentration (Cmax)	761	ng/mL	Loncastuximab tesirine 60 ug/kg once Q3W and ibrutinib 560 mg/day, Administered to patients with R/R B-cell malignancies in cycle 2.	[3]
Maximum Observed Concentration (Cmax)	2995	ug/L	PK parameters were available to be calculated from 85 patients, cycle 1	[4]
Area Under the Concentration-Time Curve (AUC)	15245	day*ug/L	PK parameters were available to be calculated from 85 patients, cycle 1	[4]
Maximum Observed Concentration (Cmax)	3155	ug/L	PK parameters were available to be calculated from 85 patients, cycle 2	[4]
Area Under the Concentration-Time Curve (AUC)	22823	day*ug/L	PK parameters were available to be calculated from 85 patients, cycle 2	[4]
Maximum Observed Concentration (Cmax)	250	ng/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 15 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	638	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 15 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	407	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 15 ug/kg	[5]
Maximum Observed Concentration (Cmax)	384	ng/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 30 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	2276	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 30 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	1945	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 30 ug/kg	[5]
Maximum Observed Concentration (Cmax)	525	ng/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 60 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	1006	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 60 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	4520	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 60 ug/kg	[5]
Maximum Observed Concentration (Cmax)	705	ng/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 90 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	1349	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 90 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	2430	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 90 ug/kg	[5]
Maximum Observed Concentration (Cmax)	2218	ng/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 120 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	10154	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 120 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	7539	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 120 ug/kg	[5]
Maximum Observed Concentration (Cmax)	2841	ng/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 150 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	10329	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 150 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	7361	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 150 ug/kg	[5]
Maximum Observed Concentration (Cmax)	3546	ng/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 200 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	24720	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 200 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	14660	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 200 ug/kg	[5]
Maximum Observed Concentration (Cmax)	329	ng/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 15 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	936	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 15 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	1030	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 15 ug/kg	[5]
Maximum Observed Concentration (Cmax)	1145	ng/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 30 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	2812	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 30 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	3264	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 30 ug/kg	[5]
Maximum Observed Concentration (Cmax)	486	ng/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 60 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	602	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 60 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	10545	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 60 ug/kg	[5]
Maximum Observed Concentration (Cmax)	1183	ng/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 90 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	3183	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 90 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	3227	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 90 ug/kg	[5]
Maximum Observed Concentration (Cmax)	2368	ng/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 120 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	13522	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 120 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	15223	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 120 ug/kg	[5]
Maximum Observed Concentration (Cmax)	3258	ng/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 150 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	16547	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 150 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	18049	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 150 ug/kg	[5]
Maximum Observed Concentration (Cmax)	4160	ng/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 200 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	44880	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 200 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	38188	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 200 ug/kg	[5]
Maximum Observed Concentration (Cmax)	178	ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 15 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	337	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 15 ug/kg	[7]
Maximum Observed Concentration (Cmax)	2150	ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 15 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	1596	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 15 ug/kg	[7]
Maximum Observed Concentration (Cmax)	258	ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 30 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	127	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 30 ug/kg	[7]
Maximum Observed Concentration (Cmax)	339	ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 30 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	735	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 30 ug/kg	[7]
Maximum Observed Concentration (Cmax)	449	ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 60 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	43	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 60 ug/kg	[7]
Maximum Observed Concentration (Cmax)	661	ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 60 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	50.6	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 60 ug/kg	[7]
Maximum Observed Concentration (Cmax)	1058	ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 90 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	671	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 90 ug/kg	[7]
Maximum Observed Concentration (Cmax)	1813	ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 90 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	3370	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 90 ug/kg	[7]
Maximum Observed Concentration (Cmax)	1291	ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 120 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	3907	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 120 ug/kg	[7]
Maximum Observed Concentration (Cmax)	1515	ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 120 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	8744	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 120 ug/kg	[7]
Maximum Observed Concentration (Cmax)	2145	ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 150 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	688	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 150 ug/kg	[7]
Maximum Observed Concentration (Cmax)	3033	ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 150 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	7553	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 150 ug/kg	[7]
Maximum Observed Concentration (Cmax)	2268	ng/mL	Summary of pharmacokinetic parameters during cycles 1 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2	[8]
Area Under the Concentration-Time Curve (AUC)	15916	ng*day/mL	Summary of pharmacokinetic parameters during cycles 1 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2,area under the concentration-time curve from time zero to last quantifiable concentration    Click to Show/Hide	[8]
Area Under the Concentration-Time Curve (AUC)	16788	ng*day/mL	Summary of pharmacokinetic parameters during cycles 1 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2, area under the concentration-time curve from zero to end of dosing interval tau	[8]
Maximum Observed Concentration (Cmax)	2746	ng/mL	Summary of pharmacokinetic parameters during cycles 2 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2	[8]
Area Under the Concentration-Time Curve (AUC)	24268	ng*day/mL	Summary of pharmacokinetic parameters during cycles 2 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2,area under the concentration-time curve from time zero to last quantifiable concentration    Click to Show/Hide	[8]
Area Under the Concentration-Time Curve (AUC)	23780	ng*day/mL	Summary of pharmacokinetic parameters during cycles 2 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2, area under the concentration-time curve from zero to end of dosing interval tau	[8]

Standard Type	Value	Units	Description	Reference
Area Under the Concentration-Time Curve (AUC)	16882	ng*day/mL	After loncastuximab tesirine treatment with the recommended dose regimen, the AUC in cycle 2 are 21,665 ng·day/mL; the AUC at steady state are 16,882 ng·day/mL	[1], [2]
Volume of Distribution (Vd)	7.11	L	The mean volume of distribution is 7.11 L.	[1], [2]
Area Under the Concentration-Time Curve (AUC)	10329	ng*day/mL	150 Ug/kg Q3W,Dose-related exposure. Administered to patients with relapsed/refractory (R/R) B-cell malignancies. In Cycle 1,	[3]
Area Under the Concentration-Time Curve (AUC)	16547	ng*day/mL	150 Ug/kg Q3W,Dose-related exposure. Administered to patients with relapsed/refractory (R/R) B-cell malignancies. In Cycle 2,	[3]
Volume of Distribution (Vd)	6.37	L	150 Ug/kg Q3W,Dose-related exposure. Administered to patients with relapsed/refractory (R/R) B-cell malignancies. In Cycle 1,	[3]
Volume of Distribution (Vd)	6.62	L	150 Ug/kg Q3W,Dose-related exposure. Administered to patients with relapsed/refractory (R/R) B-cell malignancies. In Cycle 2,	[3]
Area Under the Concentration-Time Curve (AUC)	15850	ng*day/mL	150 Ug/kg Q3W for two cycles, 75 ug/kg Q3W for subsequent cycles,Administered to patients with R/R B-cell malignancies. Dose reduced from 150 ug/kg to 75 ug/kg in cycle 1.	[3]
Area Under the Concentration-Time Curve (AUC)	23913	ng*day/mL	150 Ug/kg Q3W for two cycles, 75 ug/kg Q3W for subsequent cycles,Administered to patients with R/R B-cell malignancies. Dose reduced from 150 ug/kg to 75 ug/kg in cycle 2.	[3]
Volume of Distribution (Vd)	4.24	L	150 Ug/kg Q3W for two cycles, 75 ug/kg Q3W for subsequent cyclesAdministered to patients with R/R B-cell malignancies. Dose reduced from 150 ug/kg to 75 ug/kg in cycle 1.	[3]
Volume of Distribution (Vd)	6.4	L	150 Ug/kg Q3W for two cycles, 75 ug/kg Q3W for subsequent cycles,Administered to patients with R/R B-cell malignancies. Dose reduced from 150 ug/kg to 75 ug/kg in cycle 2.	[3]
Volume of Distribution (Vd)	5.52	L	Loncastuximab tesirine 60 ug/kg once Q3W and ibrutinib 560 mg/day, Administered to patients with R/R B-cell malignancies in cycle 1.	[3]
Volume of Distribution (Vd)	7.85	L	Loncastuximab tesirine 60 ug/kg once Q3W and ibrutinib 560 mg/day, Administered to patients with R/R B-cell malignancies in cycle 2.	[3]
Area Under the Concentration-Time Curve (AUC)	15245	day*ug/L	PK parameters were available to be calculated from 85 patients, cycle 1	[4]
Volume of Distribution (Vd)	7.19	L	PK parameters were available to be calculated from 85 patients, cycle 1	[4]
Area Under the Concentration-Time Curve (AUC)	22823	day*ug/L	PK parameters were available to be calculated from 85 patients, cycle 2	[4]
Volume of Distribution (Vd)	8.34	L	PK parameters were available to be calculated from 85 patients, cycle 2	[4]
Area Under the Concentration-Time Curve (AUC)	638	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 15 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	407	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 15 ug/kg	[5]
Volume of Distribution (Vd)	4.43	L	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 15 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	2276	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 30 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	1945	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 30 ug/kg	[5]
Volume of Distribution (Vd)	9.76	L	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 30 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	1006	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 60 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	4520	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 60 ug/kg	[5]
Volume of Distribution (Vd)	4.95	L	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 60 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	1349	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 90 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	2430	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 90 ug/kg	[5]
Volume of Distribution (Vd)	9.5	L	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 90 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	10154	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 120 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	7539	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 120 ug/kg	[5]
Volume of Distribution (Vd)	5.66	L	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 120 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	10329	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 150 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	7361	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 150 ug/kg	[5]
Volume of Distribution (Vd)	6.37	L	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 150 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	24720	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 200 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	14660	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 200 ug/kg	[5]
Volume of Distribution (Vd)	8.71	L	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 200 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	936	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 15 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	1030	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 15 ug/kg	[5]
Volume of Distribution (Vd)	3.62	L	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 15 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	2812	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 30 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	3264	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 30 ug/kg	[5]
Volume of Distribution (Vd)	8.14	L	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 30 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	602	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 60 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	10545	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 60 ug/kg	[5]
Volume of Distribution (Vd)	8.28	L	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 60 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	3183	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 90 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	3227	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 90 ug/kg	[5]
Volume of Distribution (Vd)	7.55	L	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 90 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	13522	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 120 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	15223	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 120 ug/kg	[5]
Volume of Distribution (Vd)	6.11	L	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 120 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	16547	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 150 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	18049	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 150 ug/kg	[5]
Volume of Distribution (Vd)	6.62	L	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 150 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	44880	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 200 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	38188	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 200 ug/kg	[5]
Volume of Distribution (Vd)	8.62	L	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 200 ug/kg	[5]
Volume of Distribution (Vd)	3.86	L	Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma, volume of distribution in the central compartment	[6]
Volume of Distribution (Vd)	3.53	L	Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma, volume of distribution in the peripheral compartment	[6]
Area Under the Concentration-Time Curve (AUC)	337	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 15 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	1596	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 15 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	127	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 30 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	735	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 30 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	43	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 60 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	50.6	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 60 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	671	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 90 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	3370	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 90 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	3907	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 120 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	8744	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 120 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	688	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 150 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	7553	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 150 ug/kg	[7]
Volume of Distribution (Vd)	10.5	L	Summary of PK parameters of patients on the Q3W dosing regimen (≥90 ug/kg),Cycle 1, 90 ug/kg	[7]
Volume of Distribution (Vd)	5.61	L	Summary of PK parameters of patients on the Q3W dosing regimen (≥90 ug/kg),Cycle2, 90 ug/kg	[7]
Volume of Distribution (Vd)	6.89	L	Summary of PK parameters of patients on the Q3W dosing regimen (≥90 ug/kg),Cycle 1, 120 ug/kg	[7]
Volume of Distribution (Vd)	8.33	L	Summary of PK parameters of patients on the Q3W dosing regimen (≥90 ug/kg),Cycle2, 120 ug/kg	[7]
Volume of Distribution (Vd)	34.2	L	Summary of PK parameters of patients on the Q3W dosing regimen (≥90 ug/kg),Cycle 1, 150 ug/kg	[7]
Volume of Distribution (Vd)	9.45	L	Summary of PK parameters of patients on the Q3W dosing regimen (≥90 ug/kg),Cycle2, 150 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	15916	ng*day/mL	Summary of pharmacokinetic parameters during cycles 1 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2,area under the concentration-time curve from time zero to last quantifiable concentration    Click to Show/Hide	[8]
Area Under the Concentration-Time Curve (AUC)	16788	ng*day/mL	Summary of pharmacokinetic parameters during cycles 1 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2, area under the concentration-time curve from zero to end of dosing interval tau	[8]
Volume of Distribution (Vd)	3.83	L	Summary of pharmacokinetic parameters during cycles 1 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2	[8]
Area Under the Concentration-Time Curve (AUC)	24268	ng*day/mL	Summary of pharmacokinetic parameters during cycles 2 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2,area under the concentration-time curve from time zero to last quantifiable concentration    Click to Show/Hide	[8]
Area Under the Concentration-Time Curve (AUC)	23780	ng*day/mL	Summary of pharmacokinetic parameters during cycles 2 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2, area under the concentration-time curve from zero to end of dosing interval tau	[8]
Volume of Distribution (Vd)	5.46	L	Summary of pharmacokinetic parameters during cycles 2 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2	[8]

Standard Type	Value	Units	Description	Reference
Area Under the Concentration-Time Curve (AUC)	16882	ng*day/mL	After loncastuximab tesirine treatment with the recommended dose regimen, the AUC in cycle 2 are 21,665 ng·day/mL; the AUC at steady state are 16,882 ng·day/mL	[1], [2]
Area Under the Concentration-Time Curve (AUC)	10329	ng*day/mL	150 Ug/kg Q3W,Dose-related exposure. Administered to patients with relapsed/refractory (R/R) B-cell malignancies. In Cycle 1,	[3]
Area Under the Concentration-Time Curve (AUC)	16547	ng*day/mL	150 Ug/kg Q3W,Dose-related exposure. Administered to patients with relapsed/refractory (R/R) B-cell malignancies. In Cycle 2,	[3]
Area Under the Concentration-Time Curve (AUC)	15850	ng*day/mL	150 Ug/kg Q3W for two cycles, 75 ug/kg Q3W for subsequent cycles,Administered to patients with R/R B-cell malignancies. Dose reduced from 150 ug/kg to 75 ug/kg in cycle 1.	[3]
Area Under the Concentration-Time Curve (AUC)	23913	ng*day/mL	150 Ug/kg Q3W for two cycles, 75 ug/kg Q3W for subsequent cycles,Administered to patients with R/R B-cell malignancies. Dose reduced from 150 ug/kg to 75 ug/kg in cycle 2.	[3]
Area Under the Concentration-Time Curve (AUC)	15245	day*ug/L	PK parameters were available to be calculated from 85 patients, cycle 1	[4]
Area Under the Concentration-Time Curve (AUC)	22823	day*ug/L	PK parameters were available to be calculated from 85 patients, cycle 2	[4]
Area Under the Concentration-Time Curve (AUC)	638	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 15 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	407	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 15 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	2276	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 30 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	1945	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 30 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	1006	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 60 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	4520	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 60 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	1349	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 90 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	2430	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 90 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	10154	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 120 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	7539	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 120 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	10329	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 150 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	7361	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 150 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	24720	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 200 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	14660	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 200 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	936	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 15 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	1030	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 15 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	2812	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 30 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	3264	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 30 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	602	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 60 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	10545	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 60 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	3183	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 90 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	3227	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 90 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	13522	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 120 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	15223	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 120 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	16547	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 150 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	18049	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 150 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	44880	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 200 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	38188	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 200 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	337	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 15 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	1596	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 15 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	127	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 30 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	735	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 30 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	43	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 60 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	50.6	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 60 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	671	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 90 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	3370	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 90 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	3907	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 120 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	8744	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 120 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	688	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 150 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	7553	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 150 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	15916	ng*day/mL	Summary of pharmacokinetic parameters during cycles 1 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2,area under the concentration-time curve from time zero to last quantifiable concentration    Click to Show/Hide	[8]
Area Under the Concentration-Time Curve (AUC)	16788	ng*day/mL	Summary of pharmacokinetic parameters during cycles 1 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2, area under the concentration-time curve from zero to end of dosing interval tau	[8]
Area Under the Concentration-Time Curve (AUC)	24268	ng*day/mL	Summary of pharmacokinetic parameters during cycles 2 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2,area under the concentration-time curve from time zero to last quantifiable concentration    Click to Show/Hide	[8]
Area Under the Concentration-Time Curve (AUC)	23780	ng*day/mL	Summary of pharmacokinetic parameters during cycles 2 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2, area under the concentration-time curve from zero to end of dosing interval tau	[8]

Standard Type	Value	Units	Description	Reference
Elimination Half-Life (t1/2)	7.063-12.5	days	The half-life of loncastuximab tesirine-lpyl was 7.06-12.5 days at steady-state.	[1], [2]
Clearance (CL)	0.53-0.64	L/day	In pharmacokinetic studies, the mean clearance of loncastuximab tesirine-lpyl decreased with time from 0.499 L/day after a single dose to 0.275 L/day at steady-state. One pharmacokinetic study measured a clearance ranging from 0.5-0.64 L/day.    Click to Show/Hide	[1], [2]
Area Under the Concentration-Time Curve (AUC)	16882	ng*day/mL	After loncastuximab tesirine treatment with the recommended dose regimen, the AUC in cycle 2 are 21,665 ng·day/mL; the AUC at steady state are 16,882 ng·day/mL	[1], [2]
Clearance (CL)	1.36	L/day	150 Ug/kg Q3W,Dose-related exposure. Administered to patients with relapsed/refractory (R/R) B-cell malignancies. In Cycle 1,	[3]
Clearance (CL)	0.516	L/day	150 Ug/kg Q3W,Dose-related exposure. Administered to patients with relapsed/refractory (R/R) B-cell malignancies. In Cycle 2,	[3]
Area Under the Concentration-Time Curve (AUC)	10329	ng*day/mL	150 Ug/kg Q3W,Dose-related exposure. Administered to patients with relapsed/refractory (R/R) B-cell malignancies. In Cycle 1,	[3]
Area Under the Concentration-Time Curve (AUC)	16547	ng*day/mL	150 Ug/kg Q3W,Dose-related exposure. Administered to patients with relapsed/refractory (R/R) B-cell malignancies. In Cycle 2,	[3]
Clearance (CL)	0.458	L/day	150 Ug/kg Q3W for two cycles, 75 ug/kg Q3W for subsequent cycles,Administered to patients with R/R B-cell malignancies. Dose reduced from 150 ug/kg to 75 ug/kg in cycle 1.	[3]
Clearance (CL)	0.311	L/day	150 Ug/kg Q3W for two cycles, 75 ug/kg Q3W for subsequent cycles,Administered to patients with R/R B-cell malignancies. Dose reduced from 150 ug/kg to 75 ug/kg in cycle 2.	[3]
Area Under the Concentration-Time Curve (AUC)	15850	ng*day/mL	150 Ug/kg Q3W for two cycles, 75 ug/kg Q3W for subsequent cycles,Administered to patients with R/R B-cell malignancies. Dose reduced from 150 ug/kg to 75 ug/kg in cycle 1.	[3]
Area Under the Concentration-Time Curve (AUC)	23913	ng*day/mL	150 Ug/kg Q3W for two cycles, 75 ug/kg Q3W for subsequent cycles,Administered to patients with R/R B-cell malignancies. Dose reduced from 150 ug/kg to 75 ug/kg in cycle 2.	[3]
Clearance (CL)	0.893	L/day	Loncastuximab tesirine 60 ug/kg once Q3W and ibrutinib 560 mg/day, Administered to patients with R/R B-cell malignancies in cycle 1.	[3]
Clearance (CL)	0.705	L/day	Loncastuximab tesirine 60 ug/kg once Q3W and ibrutinib 560 mg/day, Administered to patients with R/R B-cell malignancies in cycle 2.	[3]
Area Under the Concentration-Time Curve (AUC)	15245	day*ug/L	PK parameters were available to be calculated from 85 patients, cycle 1	[4]
Elimination Half-Life (t1/2)	7.15	day	PK parameters were available to be calculated from 85 patients, cycle 1	[4]
Clearance (CL)	0.75	L/day	PK parameters were available to be calculated from 85 patients, cycle 1	[4]
Area Under the Concentration-Time Curve (AUC)	22823	day*ug/L	PK parameters were available to be calculated from 85 patients, cycle 2	[4]
Elimination Half-Life (t1/2)	12.5	day	PK parameters were available to be calculated from 85 patients, cycle 2	[4]
Clearance (CL)	0.5	L/day	PK parameters were available to be calculated from 85 patients, cycle 2	[4]
Area Under the Concentration-Time Curve (AUC)	638	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 15 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	407	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 15 ug/kg	[5]
Elimination Half-Life (t1/2)	1.45	day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 15 ug/kg	[5]
Clearance (CL)	2.36	L/day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 15 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	2276	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 30 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	1945	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 30 ug/kg	[5]
Elimination Half-Life (t1/2)	6.75	day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 30 ug/kg	[5]
Clearance (CL)	1.07	L/day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 30 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	1006	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 60 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	4520	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 60 ug/kg	[5]
Elimination Half-Life (t1/2)	5.97	day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 60 ug/kg	[5]
Clearance (CL)	0.621	L/day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 60 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	1349	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 90 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	2430	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 90 ug/kg	[5]
Elimination Half-Life (t1/2)	2.54	day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 90 ug/kg	[5]
Clearance (CL)	3.33	L/day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 90 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	10154	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 120 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	7539	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 120 ug/kg	[5]
Elimination Half-Life (t1/2)	4.67	day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 120 ug/kg	[5]
Clearance (CL)	1.05	L/day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 120 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	10329	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 150 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	7361	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 150 ug/kg	[5]
Elimination Half-Life (t1/2)	4.46	day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 150 ug/kg	[5]
Clearance (CL)	1.36	L/day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 150 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	24720	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUClast, 200 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	14660	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, AUCinf, 200 ug/kg	[5]
Elimination Half-Life (t1/2)	9.02	day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 200 ug/kg	[5]
Clearance (CL)	0.998	L/day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 1 for patients with B-NHL receiving a Q3W regimen, 200 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	936	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 15 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	1030	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 15 ug/kg	[5]
Elimination Half-Life (t1/2)	3.15	day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 15 ug/kg	[5]
Clearance (CL)	0.897	L/day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 15 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	2812	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 30 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	3264	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 30 ug/kg	[5]
Elimination Half-Life (t1/2)	10.4	day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 30 ug/kg	[5]
Clearance (CL)	0.584	L/day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 30 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	602	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 60 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	10545	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 60 ug/kg	[5]
Elimination Half-Life (t1/2)	15.4	day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 60 ug/kg	[5]
Clearance (CL)	0.389	L/day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 60 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	3183	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 90 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	3227	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 90 ug/kg	[5]
Elimination Half-Life (t1/2)	7.97	day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 90 ug/kg	[5]
Clearance (CL)	1.96	L/day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 90 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	13522	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 120 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	15223	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 120 ug/kg	[5]
Elimination Half-Life (t1/2)	10.3	day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 120 ug/kg	[5]
Clearance (CL)	0.529	L/day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 120 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	16547	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 150 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	18049	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 150 ug/kg	[5]
Elimination Half-Life (t1/2)	9.77	day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 150 ug/kg	[5]
Clearance (CL)	0.516	L/day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 150 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	44880	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUClast, 200 ug/kg	[5]
Area Under the Concentration-Time Curve (AUC)	38188	ng*day/mL	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, AUCinf, 200 ug/kg	[5]
Elimination Half-Life (t1/2)	16.2	day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 200 ug/kg	[5]
Clearance (CL)	0.387	L/day	Pharmacokinetic parameters of loncastuximab tesirine during Cycle 2 for patients with B-NHL receiving a Q3W regimen, 200 ug/kg	[5]
Clearance (CL)	0.218	L/day	Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma, linear clearance	[6]
Clearance (CL)	0.0441	L/day	Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma, deconjugation clearance	[6]
Clearance (CL)	1.16	L/day	Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma, intercompartmental clearance	[6]
Area Under the Concentration-Time Curve (AUC)	337	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 15 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	1596	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 15 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	127	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 30 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	735	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 30 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	43	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 60 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	50.6	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 60 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	671	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 90 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	3370	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 90 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	3907	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 120 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	8744	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 120 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	688	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 1, 150 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	7553	day*ug/L	Summary of PK exposure in serum of patients on the Q3W dosing regimen, in relapsed/refractory B-cell acute lymphoblastic leukemia, Cycle 2, 150 ug/kg	[7]
Clearance (CL)	80.8	L/d	Summary of PK parameters of patients on the Q3W dosing regimen (≥90 ug/kg),Cycle 1, 90 ug/kg	[7]
Elimination Half-Life (t1/2)	0.355	day	Summary of PK parameters of patients on the Q3W dosing regimen (≥90 ug/kg),Cycle 1, 90 ug/kg	[7]
Clearance (CL)	9.63	L/d	Summary of PK parameters of patients on the Q3W dosing regimen (≥90 ug/kg),Cycle2, 90 ug/kg	[7]
Elimination Half-Life (t1/2)	4.96	day	Summary of PK parameters of patients on the Q3W dosing regimen (≥90 ug/kg),Cycle2, 90 ug/kg	[7]
Clearance (CL)	84.3	L/d	Summary of PK parameters of patients on the Q3W dosing regimen (≥90 ug/kg),Cycle 1, 120 ug/kg	[7]
Elimination Half-Life (t1/2)	0.156	day	Summary of PK parameters of patients on the Q3W dosing regimen (≥90 ug/kg),Cycle 1, 120 ug/kg	[7]
Clearance (CL)	31.1	L/d	Summary of PK parameters of patients on the Q3W dosing regimen (≥90 ug/kg),Cycle2, 120 ug/kg	[7]
Elimination Half-Life (t1/2)	7.55	day	Summary of PK parameters of patients on the Q3W dosing regimen (≥90 ug/kg),Cycle2, 120 ug/kg	[7]
Clearance (CL)	27.4	L/d	Summary of PK parameters of patients on the Q3W dosing regimen (≥90 ug/kg),Cycle 1, 150 ug/kg	[7]
Elimination Half-Life (t1/2)	0.713	day	Summary of PK parameters of patients on the Q3W dosing regimen (≥90 ug/kg),Cycle 1, 150 ug/kg	[7]
Clearance (CL)	1.57	L/d	Summary of PK parameters of patients on the Q3W dosing regimen (≥90 ug/kg),Cycle2, 150 ug/kg	[7]
Elimination Half-Life (t1/2)	3.99	day	Summary of PK parameters of patients on the Q3W dosing regimen (≥90 ug/kg),Cycle2, 150 ug/kg	[7]
Area Under the Concentration-Time Curve (AUC)	15916	ng*day/mL	Summary of pharmacokinetic parameters during cycles 1 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2,area under the concentration-time curve from time zero to last quantifiable concentration    Click to Show/Hide	[8]
Area Under the Concentration-Time Curve (AUC)	16788	ng*day/mL	Summary of pharmacokinetic parameters during cycles 1 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2, area under the concentration-time curve from zero to end of dosing interval tau	[8]
Elimination Half-Life (t1/2)	8.25	day	Summary of pharmacokinetic parameters during cycles 1 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2	[8]
Clearance (CL)	0.464	L/day	Summary of pharmacokinetic parameters during cycles 1 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2	[8]
Area Under the Concentration-Time Curve (AUC)	24268	ng*day/mL	Summary of pharmacokinetic parameters during cycles 2 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2,area under the concentration-time curve from time zero to last quantifiable concentration    Click to Show/Hide	[8]
Area Under the Concentration-Time Curve (AUC)	23780	ng*day/mL	Summary of pharmacokinetic parameters during cycles 2 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2, area under the concentration-time curve from zero to end of dosing interval tau	[8]
Elimination Half-Life (t1/2)	13	day	Summary of pharmacokinetic parameters during cycles 2 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2	[8]
Clearance (CL)	0.321	L/day	Summary of pharmacokinetic parameters during cycles 2 for patients treated with loncastuximab tesirine 150 ug/kg Q3Wx 2	[8]

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Objective Response Rate (ORR)	NCT03589469	Phase 2	A phase 2 open-label single-arm study to evaluate the efficacy and safety of loncastuximab tesirine in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (LOTIS-2).
Objective Response Rate (ORR)	NCT02669017	Phase 1	A phase 1 dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory b-cell lineage non Hodgkin lymphoma (B-NHL).    Click to Show/Hide
Complete Remission (CR)	NCT02669017	Phase 1	A phase 1 dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma (B-NHL).    Click to Show/Hide
Complete Remission (CR)	NCT02669264	Phase 1	A phase 1, open-label, adaptive dose-escalation, multicenter study to evaluate the tolerability, safety, pharmacokinetics, and anti-tumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage acute lymphoblastic leukemia (B-ALL).    Click to Show/Hide
Complete Remission (CR)	Undisclosed	Undisclosed	This study evaluated the outcomes of 13 DLBCL patients relapsed after CAR-T cells treated with loncastuximab in the LOTIS-2 trial.

Experiment 1 Reporting the Activity Date of This ADC					[9]
Efficacy Data	Objective Response Rate (ORR)	48.28%
Patients Enrolled	Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more multiagent systemic treatments, who had measurable disease and Eastern Cooperative Oncology Group performance status 0-2.
Administration Dosage	Intravenously on day 1 of each 21-day cycle, at 150 ug/kg for two cycles, then 75 ug/kg thereafter, for up to 1 year or until disease relapse or progression, unacceptable toxicity, death, major protocol deviation, pregnancy, or patient, investigator, or sponsor decision.
Related Clinical Trial
NCT Number	NCT03589469	Clinical Status	Phase 2
Clinical Description	A phase 2 open-label single-arm study to evaluate the efficacy and safety of loncastuximab tesirine in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (LOTIS-2).
Primary Endpoint	Overall response rate assessed by central review. 70 of 145 patients had complete or partial response (overall response rate 48.28% [95% CI 39.9-56.7]); 35 had complete response and 35 had partial response.
Other Endpoint	Median time to first response (complete response or partial response) was 41.00 days (IQR 38.00-44.00). Median duration of response was 10.30 months (95% CI 6.9-not estimable); 13.40 months (10.30-not estimable) for patients with complete response and 5.70 months (1.70-not estimable) for patients with partial response. The probability of responders maintaining responses for 9 months or longer was 64.0%. Median progressionfree survival was 4.90 months (95% CI 2.90-8.30), median overall survival was 9.90 months (6.70-11.50), and median relapse-free survival was 13.40 months (10.30-not estimable).    Click to Show/Hide
Experiment 2 Reporting the Activity Date of This ADC					[10]
Efficacy Data	Objective Response Rate (ORR)	59.40%
Patients Enrolled	R/R B-cell non Hodgkin lymphoma (NHL); had failed or were intolerant to established therapies, or for whom no other established treatment options were available.
Administration Dosage	5 to 200 ug/kg; intravenously over 1 hour, once every 3 weeks (one cycle) by a 3+3 dose-escalation design.
Related Clinical Trial
NCT Number	NCT02669017	Clinical Status	Phase 1
Clinical Description	A phase 1 dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory b-cell lineage non Hodgkin lymphoma (B-NHL).
Primary Endpoint	The MTD was not established during the trial due to the low level of DLTs, 150 ug/kg dose for expansion and phase 2.
Other Endpoint	For loncastuximab tesirine 120 ug/kg,Median Progression-Free Survival (mPFS)=4.80 months.The median PFS OS=11.60 months.
Experiment 3 Reporting the Activity Date of This ADC					[11]
Efficacy Data	Complete Remission (CR)	26.70%
Patients Enrolled	Adults (age 18 years) with histologically confirmed relapsed/refractory B-non Hodgkin lymphoma (World Health Organization 2008 classification18 ) who were intolerant to established therapy, for whom established therapy had failed, or for whom no other treatment options were available in the opinion of the investigator were eligible to participate.
Administration Dosage	3 + 3 dose escalation at 15 to 200 ug/kg and dose expansion at 120 and 150 ug/kg; IV infusion over 60 minutes once every 3 weeks (day 1 of each 21-day cycle).
Related Clinical Trial
NCT Number	NCT02669017	Clinical Status	Phase 1
Clinical Description	A phase 1 dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin lymphoma (B-NHL).
Primary Endpoint	The recommended dose of loncastuximab tesirine for Phase 2 is 150 ug/kg Q3W for 2 doses followed by 75 ug/kg Q3W for subsequent doses. The 150 ug/kg dose was selected as a dose with encouraging responses but lower frequency of AEs than observed with the 200 u/kg dose. Overall response rate (ORR) in evaluable patients was 45.60%, including 26.70% complete responses (CR). Median PFS was 3.10 months (95% CI 2.70-4.20) in all patients with B-NHL, 2.8 months (95% CI 1.90-3.80) in patients with DLBCL, 4.80 months (95% CI 1.10-7.80) in patients with MCL, and could not be determined in those with FL due to the low number of events. Median OS was 8.3 months (95% CI 6.70-10.70) in all patients with B-NHL, 7.5 months (95% CI 6.00-9.80) in patients with DLBCL, and was not reached in patients with MCL or FL due to low number of events.    Click to Show/Hide
Other Endpoint	PK exposure similarity between loncastuximab tesirine total antibody and PBD-conjugated antibody indicated good stability in serum.Accumulation by Cycle 2 for patients on a Q6W dosing regimen was lower than that of those on Q3W dosing: mean accumulation of 1.22 and 1.33 for PBD-conjugated antibody and total antibody on Q6W regimens compared with 1.72 and 1.74 on Q3W regimens. There was substantial variability in PK exposure and PK parameters assessed for PBD-conjugated antibody, total antibody, and SG3199.    Click to Show/Hide
Experiment 4 Reporting the Activity Date of This ADC					[12]
Efficacy Data	Complete Remission (CR)	40.20%
Patients Enrolled	R/R B-acute lymphocytic leukemia (ALL) for standard therapies had failed, intolerant to standard therapies, or no other treatment options were available, in the opinion of the investigator, were eligible for the study, other key inclusion criteria included Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
Administration Dosage	15 to 150 ug/kg once every 3 weeks (Q3W) or 50 ug/kg IV weekly.
Related Clinical Trial
NCT Number	NCT02669264	Clinical Status	Phase 1
Clinical Description	A phase 1, open-label, adaptive dose-escalation, multicenter study to evaluate the tolerability, safety, pharmacokinetics, and anti-tumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage acute lymphoblastic leukemia (B-ALL).
Primary Endpoint	Part II (dose expansion portion) utilized the doses of 120 and 150 ug/kg, selected based on antitumor activity and tolerability seen during part I. The overall response rate (ORR) in patients with DLBCL, mantle cell lymphoma, and follicular lymphoma was 42.30%, 46.70%, and 78.60%, respectively.
Other Endpoint	The median progression-free survival (PFS) was 3.10 months in all patients with B-NHL and 2.80 months in patients with DLBCL, whereas the median OS was 8.30 months in all patients and 7.50 months in patients with DLBCL.
Experiment 5 Reporting the Activity Date of This ADC					[13]
Efficacy Data	Complete Remission (CR)	46.16%

Ref 1	ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies
Ref 2	Loncastuximab Tesirine: First Approval
Ref 3	Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma
Ref 4	A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Ref 5	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma
Ref 6	Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma
Ref 7	Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia
Ref 8	Loncastuximab tesirine in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter, open-label, single-arm, phase II trial
Ref 9	Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2021 Jun;22(6):790-800.
Ref 10	A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. Clin Cancer Res. 2019 Dec 1;25(23):6986-6994.
Ref 11	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
Ref 12	Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia. Blood Adv. 2020 Feb 11;4(3):449-457.
Ref 13	The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy. Clin Lymphoma Myeloma Leuk. 2022 May;22(5):e335-e339.